SMAD7 and Hepatic fibrosis: Our results established a recent approach associating the anti-fibrotic mechanism of the non-selective β-blocker Carvedilol with the circulating miR-200a, the newly diagnostic non-invasive biomarkers of liver fibrosis, SMAD7, and through the suppression of EMT.